ViiV Healthcare unveils positive data from CUSTOMIZE trial
ViiV Healthcare has unveiled positive initial findings from the Cabotegravir plus Rilpivirine in the US to optimise and measure implementation and experience (CUSTOMIZE) trial. The clinical study is